Short Sleep Syndrome Treatment Market

Short Sleep Syndrome Treatment Market Overview

Short sleep syndrome is a sleep condition in which an individual gets less than six hours of sleep. The growing stress levels, especially in adults, have resulted in increasing no. of psychological disorders worldwide.

The most common psychological problems that are witnessed are depression and anxiety disorders. These disorders often interfere with sleeping patterns of individuals. The increasing prevalence of these disorders has led to the sleep syndrome treatment market evolve over the last few years.

The impact of COVID-19 on short sleep syndrome treatment market has started to be felt. The breakout of this disease led to lockdowns across globe which has slowed down the growth of many markets. Short sleep syndrome treatment market is no different. 

However, the virus has led to major losses in business and as consequences many employees have been laid off across the globe. This may lead to rise in the no. of cases with psychological disorders and is expected to boost the growth of short sleep syndrome market during the forecast period.

Short Sleep Syndrome Treatment Market: Drivers and Restraints

Short sleep syndrome treatment market is expected to grow substantially due to increasing stress as a result of highly active lifestyles of individuals. The increasing usage of media devices world-wide is also expected to boost the growth of the short sleep syndrome treatment market.  

However, the misconception about the seriousness of insomnia may restrict the growth of the market. Patient non-adherence due to characteristic side effects of insomnia drugs may also restrain the growth of the short sleep syndrome treatment market.

Short Sleep Syndrome Treatment Market: Overview

The global market for short sleep syndrome treatment is expected to grow at a steady rate in the forecast period. On the basis of drug class, the short sleep treatment is segmented into benzodiazepines, nonbenzodiazepines, antidepressants, orexin antagonist, melatonin antagonist and others.  

Antidepressants are expected to witness significant growth in the short sleep syndrome treatment market in this segment during forecast period. However, benzodiazepines is also expected to be a great contributor towards the growth of the short sleep syndrome treatment market. On the basis of distribution channel, the global short sleep syndrome treatment is segmented into hospital pharmacies, retail pharmacies, drug stores and online pharmacies.

Short Sleep Syndrome Treatment Market: Regional-Wise Outlook

Geographically, the short sleep syndrome treatment market is segmented into seven regions viz. South Asia, East Asia, Europe, Latin America, North America, Oceania and Middle East and Africa. The North America is expected to account for the largest share in the short sleep syndrome treatment market due to growing need of treatment for sleep disorders coupled with increasing prevalence of sleep disorders in this region.

Due to Increasing awareness and rise in healthcare spending, Europe is expected to have 2nd largest share in the global short sleep syndrome treatment. East Asia is expected to observe a substantial growth in the short sleep syndrome treatment market due to availability of funds for research and development.

However, the rapidly growing geriatric population and increasing prevalence of sleep disorders and stress in developing countries in this region is expected to contribute towards highest growth in South Asia. In the Middle East and Africa the market growth is expected to be limited due to slow economic growth, underdeveloped infrastructure and lower access to technological advancement.

Sabyasachi Ghosh

Principal Consultant

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Talk to Analyst

Short Sleep Syndrome Treatment Market: Key players

Some of the players identified in the short sleep syndrome treatment market include:

• Merck & co.
• Mylan N.V.
• Paratek pharmaceuticals
• Pfizer Inc.
• Sanofi S.A.
• Sumitomo Dainippon pharma Co. Ltd.
• Takeda Pharmaceuticals Company Ltd.
• Teva Pharmaceutical Industries Ltd.
• Vanda Pharmaceuticals Inc.

The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain.

The report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.

• Market Segments
• Market Dynamics
• Market Size
• Supply & Demand
• Current Trends/Issues/Challenges
• Competition & Companies involved
• Technology Matrix
• Value Chain

Regional analysis of the short sleep syndrome treatment market report includes

• North America
• Latin America
• Europe
• South  Asia
• East Asia
• Oceania
• Middle East and Africa

Become a MarketNgage Insider

An unified Market Research Subscription Platform, built for today’s disparate research needs.

Sign-Up

Short Sleep Syndrome Treatment Market: Segmentation

Tentatively, the global short sleep syndrome treatment market has been segmented on the basis of drug class, distribution channel and region.

By Drug Class:

• Benzodiazepines
• Nonbenzodiazepines
• Antidepressants
• Orexin Antagonist
• Melatonin Antagonist
• Other

By Distribution Channel:

• Hospital pharmacies
• Retail pharmacies
• Drug stores
• Online pharmacies